Covidien Launches New Capnography Monitoring Solution

North America, United States

Capnostream® 20p bedside monitor offers enhanced features for increasing patient safety in hospitals

11/10/2013 — BOULDER, Colo. — (BUSINESS WIRE)

Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today launched the Capnostream® 20p bedside monitor. The new capnography solution, with Covidien’s Microstream® technology, offers enhanced features that will help clinicians identify and address serious health threats sooner.

For nearly two decades, clinicians have relied on Microstream capnography monitoring for an integrated, complete picture of oxygenation and ventilation. These factors can help clinicians appropriately manage sedation levels and ensure safe administration of opioids for pain management. The Capnostream 20p bedside monitor features the Apnea-Sat Alert™ algorithm, which measures and reports recurring apnea (temporary cessation of breathing for more than 10 seconds) and oxygen desaturation events.

Frequent apneic events can provide clinicians early warning of cardiopulmonary complications. Coupling the new Apnea-Sat Alert feature with trusted capnography technology from Covidien may facilitate early detection and treatment of cardiac arrest and others serious conditions.

“Studies show that as many as 88% of hospitalized patients may be at risk for recurrent apneas, yet we’re only identifying and treating a very small number,*” said Scott Kelley, M.D., Chief Medical Officer, Respiratory and Monitoring Solutions, Covidien. “The Capnostream 20p bedside monitor will help increase apnea detection rates and represents an important advancement in continuous patient monitoring that we believe will help save lives.”

The Apnea-Sat Alert feature detects apneas per hour and oxygen desaturation fluctuations, displaying the values on the Capnostream 20p monitor screen without requiring additional equipment or clinical workflow changes.

Apnea-Sat Alert technology is a part of the broader family of Smart Alarm Management™ integrated algorithms that help mitigate alarm fatigue while meeting Joint Commission guidelines for alarm management. These include:

  • Smart Breath Detection™, a proprietary filter and pattern recognition algorithm that screens out low-amplitude “non-breath” etCO2 excursions like snoring, talking or crying, to provide a more accurate respiratory rate.
  • Smart Alarm for Respiratory Analysis (SARA™), alarm management technology that helps prevent alarm fatigue by reducing clinically insignificant respiratory alarms.
  • Nellcor™ SatSeconds, technology that helps analyze oxygen desaturation events.
  • Integrated Pulmonary IndexTM (IPI) an algorithm that combines four respiratory measurements–capnography, respiratory rate, pulse rate and pulse oximetry–to provide clinicians with an integrated snapshot of respiratory status.

The Capnostream 20p bedside monitor is further differentiated by the Microstream-enabled microMediCO2 module measurement bench. The module offers easy integration into host monitor configurations and is designed to support future Smart Capnography algorithms without requiring hardware upgrades.

The Capnostream 20p bedside monitor can be used across all care settings and complies with ISO alarm standards. For more information about the device, visit www.covidien.com/rms/pages.aspx?page=Product/Capnostream-20p-Bedside-Patient-Monitor.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

*Sources

  • Kumar S, McElligott D, Goyal A, Baugh M, Ionita RN. Risk of obstructive sleep apnea (OSA) in hospitalized patients. Chest. 2010;138(4):779A.
  • Frey WC, Pilcher J: Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 2003; 13:676-683.
  • Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;29;328(17):1230-1235.


CONTACT:

R&MS Communications
Rhonda Luniak, 303-406-8743
Vice President
rhonda.luniak@covidien.com
or
Covidien
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

 

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Medical Devices  Pharmaceutical  Medical Supplies

MEDIA:

Logo
 Logo